Deals

Deal activity by volume related to ESG increased by 50% year-on-year in 2022 in the pharmaceutical industry

Credit: Bert van Dijk/Getty images.

Powered by

Analysis of the key themes driving deal activity reveals that ESG accounted for 314 pharmaceutical deals between 2018 and 2022, worth a total value of $131,024m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships.  

The $60m acquisition of ACT Genomics by Prenetics Global was the largest disclosed deal in 2022, while the $85m acquisition of Notch Therapeutics by Lumira Capital Investment Management was the largest disclosed deal in 2021.  

In volume terms, ESG related deal activity decreased by 50% year-on-year in 2022 and by 86% in 2021.

Deal activity related to ESG in the global pharmaceutical industry in the last five years

Top deals related to ESG in the pharmaceutical industry in the last five years

Deal volume by deal type for ESG related deals in the pharmaceutical industry in the last five years

Licensing agreements accounted for the highest number of deals in the last five years, with 176 deals, followed by partnerships (52 deals), and acquisitions (31 deals).

Top financial advisors for ESG related deals by value in the pharmaceutical industry in the last five years

The top financial advisors supporting deals related to ESG in the pharmaceutical industry in the last five years in terms of value were Goldman Sachs International, Deutsche Bank, Morgan Stanley, BNP Paribas, and Barclays Bank.

Top legal advisors for ESG related deals by value in the pharmaceutical industry in the last five years

The top legal advisors supporting deals related to ESG in the pharmaceutical industry in the last five years in terms of value were White & Case, Latham & Watkins, Fried, Frank, Harris, Shriver & Jacobson, Linklaters, and Arthur Cox.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.

Go to article: Home | Nanoparticle drug delivery research gets a boostGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: NiproGo to article: In DepthGo to article: Covid-19 vaccine success bolsters nanoparticle drug delivery research Go to article: eConsent in clinical trials: What’s on the horizon?Go to article: Breathing easy: How digital inhalers are changing asthma treatmentGo to article: Primate models in pharma: What the future holds Go to article: A decade on, what’s next for CAR-T therapies?Go to article: FDA’s $7bn plan for 2024: Disclose CMOs, restart Cancer MoonshotGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: ForewordGo to article: ESG is the most important theme of this decadeGo to article: A timeline of corporate ESGGo to article: The most pressing ESG concerns for the pharma industryGo to article: Key trends impacting ESG performance in the healthcare sectorGo to article: Latest news: ESG in pharmaGo to article: Sustainable supply chains: Clinical trials in a new era of limited resourcesGo to article: Increase in DPI use could lead to decreases in greenhouse gas emissionsGo to article: Environmental sustainability innovation: Leading companies in anti-malarial compositionsGo to article: Deal activity related to ESG in the pharmaceutical industry since 2020Go to article: ESG hiring trends in the global pharmaceutical industry since 2020Go to article: ESG patent applications in the global pharmaceutical industry since 2020Go to article: Mentions of ESG in pharmaceutical industry company filings since 2020 Go to article: GlobalData Thematic IntelligenceGo to article: Pharma Sponsored SupplementsGo to article: CfPIEGo to article: ListingsGo to article: EventsGo to article: RankingsGo to article: Buyer's GuidesGo to article: Next issue